Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Literature DB >> 31056762

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Victor A Chow^1,2,3, Ajay K Gopal^1,2,3, David G Maloney^1,2,3, Cameron J Turtle^1,2,3, Stephen D Smith^1,2,3, Chaitra S Ujjani^1,2,3, Mazyar Shadman^1,2,3, Ryan D Cassaday^1,2,4, Brian G Till^1,2,3, Yolanda D Tseng^2,5, Edus H Warren^1,2,3, Andrei R Shustov^1,2,4, Manoj P Menon^1,4, Sandra Bhark^2,6, Utkarsh H Acharya^1,2,3,7, Erin Mullane², Lindsay M Hannan^1,2,3, Jenna M Voutsinas⁸, Ted A Gooley^1,8, Ryan C Lynch^1,2,3.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2019 PMID： 31056762 PMCID： PMC6776079 DOI： 10.1002/ajh.25505

Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047

× No keyword cloud information.

6 in total

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors: Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal: Blood Date: 2017-08-03 Impact factor: 22.113

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors: Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245

Review 3. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Authors: Victor A Chow; Mazyar Shadman; Ajay K Gopal
Journal: Blood Date: 2018-06-18 Impact factor: 22.113

4. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Authors: E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; R Bouadballah; J Radford; M Bargetzi; V Ribrag; U Dührsen; D Ma; J Briere; C Thieblemont; E Bachy; C H Moskowitz; B Glass; C Gisselbrecht
Journal: Bone Marrow Transplant Date: 2016-09-19 Impact factor: 5.483

5. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors: Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245

6. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors: Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544

6 in total

26 in total

1. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Authors: M Lia Palomba; Joachim Yahalom; Brandon S Imber; Michel Sadelain; Carl DeSelm; Connie Batlevi; Renier J Brentjens; Parastoo B Dahi; Sergio Giralt; Jae H Park; Craig Sauter; Michael Scordo; Gunjan Shah; Miguel-Angel Perales
Journal: Br J Haematol Date: 2020-03-05 Impact factor: 6.998

2. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.

Authors: Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt
Journal: Blood Adv Date: 2020-12-22

3. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.

Authors: Victor A Chow; Ajay K Gopal; Jordan Gauthier; Yolanda D Tseng; Cameron J Turtle; David G Maloney; Mazyar Shadman
Journal: Blood Adv Date: 2020-10-13

4. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Authors: Mazyar Shadman; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Filippo Milano; Ang Li; Alexandre V Hirayama; Mohamed L Sorror; Sindhu Cherian; Xueyan Chen; Ryan D Cassaday; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; David G Maloney; Cameron J Turtle
Journal: Blood Adv Date: 2019-10-22

Review 5. Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors: Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal: Biol Blood Marrow Transplant Date: 2020-01-07 Impact factor: 5.742

Review 6. Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.

Authors: Anagha Deshpande; William Rule; Allison Rosenthal
Journal: Curr Treat Options Oncol Date: 2022-02-15

7. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

Authors: Nirav N Shah; Kwang W Ahn; Carlos Litovich; Yizeng He; Craig Sauter; Timothy S Fenske; Mehdi Hamadani
Journal: Blood Date: 2021-03-11 Impact factor: 22.113

8. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

Authors: Jay Y Spiegel; Saurabh Dahiya; Michael D Jain; John Tamaresis; Loretta J Nastoupil; Miriam T Jacobs; Armin Ghobadi; Yi Lin; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Andre Goy; Khoan Vu; Charalambos Andreadis; Javier Munoz; N Nora Bennani; Julie M Vose; Kathleen A Dorritie; Sattva S Neelapu; Frederick L Locke; Aaron P Rapoport; Brian T Hill; David B Miklos
Journal: Blood Date: 2021-04-01 Impact factor: 22.113

Review 9. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.

Authors: Jennifer M Logue; Julio C Chavez
Journal: Curr Treat Options Oncol Date: 2021-10-26

Review 10. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

Authors: Faroogh Marofi; Marwan Mahmood Saleh; Heshu Sulaiman Rahman; Wanich Suksatan; Moaed E Al-Gazally; Walid Kamal Abdelbasset; Lakshmi Thangavelu; Alexei Valerievich Yumashev; Ali Hassanzadeh; Mahboubeh Yazdanifar; Roza Motavalli; Yashwant Pathak; Adel Naimi; Behzad Baradaran; Marzieh Nikoo; Farhad Motavalli Khiavi
Journal: Stem Cell Res Ther Date: 2021-07-02 Impact factor: 6.832